HL
Steven L. McCabe, PhD, brings decades of expertise in engineering, particularly in earthquake hazard reduction efforts, to his role as Director, Disaster Impact Reduction Office at the National Institute of Standards and Technology (NIST). With a robust academic background including a Doctor of Philosophy in civil engineering from the University of Illinois Urbana-Champaign, Dr. McCabe has been instrumental in managing critical national programs such as the National Windstorm Impact Reduction Program (NWIRP) and the National Earthquake Hazards Reduction Program (NEHRP). His leadership extends to disaster and failure studies, enhancing building safety standards against natural disasters.
Dr. McCabe's career is marked by significant contributions to earthquake hazard reduction and leadership roles in both academic and governmental sectors. He is a Licensed Professional Engineer in Kansas and Colorado, affiliated with professional organizations including ASCE, ASME, ACI, and EERI. Beyond his professional endeavors, Dr. McCabe actively participates in local community and charitable initiatives.
With his wife Annie by his side, Dr. McCabe enjoys spectator sports and has a fondness for dogs. He attributes much of his career success to the guidance of his mentor, Dr. William J. Hall.
Looking forward, Dr. McCabe is committed to ensuring the reauthorization and adequate funding of statutory programs under his leadership at NIST. His future projections include further enhancing building safety standards to mitigate natural disaster risks, reflecting his ongoing dedication to engineering excellence and public safety.
Contact: Katherine Green, 516-825-5634, editorialteam@continentalwhoswho.com
View original content:https://www.prnewswire.com/news-releases/hl-302497734.html
SOURCE The Inner Circle
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
The Tiny Habit That Could Be Fueling Your Anxiety Without You Knowing It
Chances are you don't realize the impact anxiety can have on guys. Studies continuously show that women are twice as likely as men to be diagnosed with an anxiety disorder–but that doesn't mean you're immune. Researchers can't explain the causes of this disparity, but believe guys may feel pressured to exhibit anxious feelings in ways that seem more masculine. 'I think the biggest thing is men are socialized not to show anxiety,' said Carmen McLean, PhD, a researcher and clinical associate professor at Stanford University's Department of Psychiatry. 'Socializing to show agency and self-efficiency dissuades from showing anxiety.' This is one reason anxiety is often accompanied by substance abuse and other 'internalizing disorders, ' said McLean. Sometimes these signs can be subtle, meaning it's especially important to recognize symptoms of anxiety disorders specific to males. Some clues—nervousness, dread over impending danger and rapid breathing—are common across gender lines, but these five manifestations of anxiety disproportionately impact men: Men with social anxiety disorder are more likely to fear dating and are more commonly single, separated or divorced, according to an analysis of survey information from Columbia University. 'Men are supposed to take the lead in dating,' explained Stefan G. Hofmann, PhD and psychology professor at Boston University who researches anxiety. 'The male is the one who is expected to take the first step. That puts them in a performance situation.' Even in the age of apps, men are typically the pursuer. On OkCupid, males are three times more likely to send a first message in an opposite-sex exchange. This means constantly offering yourself up for evaluation and rejection–an anxiety-inducing prospect. 'It's a challenge for people who don't like to play that game,'said Hofman. Plus, some agonize over being chronically single–with reason–David Ezell, clinical director of Darien Wellness, a psychology clinic in Connecticut, told Men's Health. 'Men really benefit from marriage,' Ezell said. 'They're less likely to be sick. They're less likely to be hospitalized. They're hospitalized for shorter stays if they are hospitalized.' Also, marriage is a status symbol, a sign of 'maturation,' said Ezell. With so much at risk, dating and bachelorhood are significant sources of stress in men with anxiety. Men drink and use drugs to relieve anxiety more often than women, according to the same Columbia University study. Research has consistently shown a link between substance abuse and mental health disorders, particularly in men. 'They are looking for medication,' said Ezell. He explains a glass of booze pairs well with the 'I-can-fix-it-myself' attitude associated with masculinity because it doesn't require medical assistance and may seem like a socially acceptable way to ease stress. 'Alcohol is a very effective drug,' said Hofmann. 'It's why it's so popular.' Think about college students who 'pre-game" by drinking at a dorm or with a small group of friends before going to larger parties. They may not realize it, but this helps manage the anxiety of socializing. Guys who forego professional treatment may instead turn to drugs or heavy drinking to cope with anxiety–and this may be a doorway to addiction. In some men, anxiety may manifest as rage or anger. 'It's much more acceptable,' said McLean. While women may find support from friends or mental health professionals, guys often let their feelings build up until they hit a breaking point–and then the flood gates open. 'Because emotions don't get expressed [by men], because anxiety isn't expressed in a healthy way, there are busts of anger as a result,' said Ezell. 'I think anger is considered decisive.' If typical signs of anxiety, like nervousness or fear, are discouraged in men, anger is their only acceptable emotional response. In another study of survey data from Columbia University, men were more likely than women to experience relationship strain from worrying. This could be because women are more likely to have a circle of close friends, whereas men tend to have few confidants who can provide support through emotional distress. 'Men tend to rely on romantic partners for stress,' said Hofman. This can be a burden, he explained. Sociologist Eli J. Finkel further detailed the risk of putting all that psychological dependence on one person in his book, The All-Or-Nothing Marriage. Finkel argued that modern relationships are tense because people seek comfort, growth, purpose, and a host of other needs from romantic partnerships. Prior generations sought comfort in an entire network of family and friends. 'Marriage for a long time served a set and relatively limited array of different functions for us,' Finkel told the NPR podcast Hidden Brain. 'And over time we've piled more and more of these emotional and psychological functions." Anxious men might burn out their few outlets (or only outlet) for social support quickly. Ezell's practice is located in Darien, Connecticut, a bedroom community for hedge fund managers and Wall Street executives. With a median family income of $208,125, it's frequently named one of the wealthiest municipalities in the United States. Despite their success, Ezell has clients who are riddled with anxiety over what they haven't accomplished. 'My clients make a lot of money,' said Ezell. 'They are still not happy and want to know why.' Guys are often anxious about getting ahead of peers, he said. If a friend winters in Aspen, his client wants to winter in the Alps. There is a particular pressure in status attainment—and status advancement—that fuels anxiety disorders for many. 'We are very grateful by getting things,' Ezell said, 'but we get acclimated to that status very quickly. If I am eating well; I want to be eating better.' You Might Also Like The Best Hair Growth Shampoos for Men to Buy Now 25 Vegetables That Are Surprising Sources of Protein
Yahoo
25 minutes ago
- Yahoo
Skye Bioscience Highlights Nimacimab's Promise in Obesity Treatment, Anticipates Phase 2a Data
Skye Bioscience Inc. (NASDAQ:SKYE) is one of the best hot stocks to buy according to Wall Street analysts. On June 23, Skye Bioscience unveiled its 'Anatomy of Progress' nimacimab development update video series. This coincided with the presentation of data related to nimacimab at the American Diabetes Association's/ADA 85th Scientific Sessions, which was held from June 20 to 23 this year in Chicago, Illinois. The four-part 'Anatomy of Progress' video series highlights unmet needs in obesity treatment, the benefits of nimacimab as a peripheral CB1-receptor-targeting antibody for healthy weight loss, and its development progress. Nimacimab's unique mechanism targets receptors in the periphery while being greater than 99% excluded from the brain. This peripheral restriction aims to deliver weight loss and metabolic benefits similar to first-gen CB1 inhibitors, but without the neuropsychiatric side effects that plagued earlier small-molecule counterparts. A scientist in the lab, researching the development of biopharmaceutical monoclonal antibody drugs. Skye Bioscience is currently conducting a Phase 2a clinical trial in obesity for nimacimab, which is a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing nimacimab in combination with a GLP-1R agonist (Wegovy). Interim data from the Phase 2a clinical trial are expected in late Q3 or early Q4 2025, after the initial patient cohort completes a 26-week treatment period. Skye Bioscience Inc. (NASDAQ:SKYE) is a clinical-stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors/GPCRs to treat obesity and metabolic diseases. While we acknowledge the potential of SKYE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Weedkiller ingredient widely used in US can damage organs and gut bacteria, research shows
The herbicide ingredient used to replace glyphosate in Roundup and other weedkiller products can kill gut bacteria and damage organs in multiple ways, new research shows. The ingredient, diquat, is widely employed in the US as a weedkiller in vineyards and orchards, and is increasingly sprayed elsewhere as the use of controversial herbicide substances such as glyphosate and paraquat drops in the US. But the new piece of data suggests diquat is more toxic than glyphosate, and the substance is banned over its risks in the UK, EU, China and many other countries. Still, the EPA has resisted calls for a ban, and Roundup formulas with the ingredient hit the shelves last year. Related: 'We thought we'd got the numbers wrong': how a pristine lake came to have the highest levels of 'forever chemicals' on record 'From a human health perspective, this stuff is quite a bit nastier than glyphosate so we're seeing a regrettable substitution, and the ineffective regulatory structure is allowing it,' said Nathan Donley, science director with the Center For Biological Diversity, which advocates for stricter pesticide regulations but was not involved in the new research. 'Regrettable substitution' is a scientific term used to describe the replacement of a toxic substance in a consumer product with an ingredient that is also toxic. Diquat is also thought to be a neurotoxin, carcinogen and linked to Parkinson's disease. An October analysis of EPA data by the Friends of the Earth non-profit found it is about 200 times more toxic than glyphosate in terms of chronic exposure. Bayer, which makes Roundup, faced nearly 175,000 lawsuits alleging that the product's users were harmed by the product. Bayer, which bought Monsanto in 2018, reformulated Roundup after the International Agency for Research on Cancer classified glyphosate as a possible carcinogen. The new review of scientific literature in part focuses on the multiple ways in which diquat damages organs and gut bacteria, including by reducing the level of proteins that are key pieces of the gut lining. The weakening can allow toxins and pathogens to move from the stomach into the bloodstream, and trigger inflammation in the intestines and throughout the body. Meanwhile, diquat can inhibit the production of beneficial bacteria that maintain the gut lining. Damage to the lining also inhibits the absorption of nutrients and energy metabolism, the authors said. The research further scrutinizes how the substance harms the kidneys, lungs and liver. Diquat 'causes irreversible structural and functional damage to the kidneys' because it can destroy kidney cells' membranes and interfere with cell signals. The effects on the liver are similar, and the ingredient causes the production of proteins that inflame the organ. Meanwhile, it seems to attack the lungs by triggering inflammation that damages the organ's tissue. More broadly, the inflammation caused by diquat may cause multiple organ dysfunction syndrome, a scenario in which organ systems begin to fail. The authors note that many of the studies are on rodents and more research on low, long-term exposure is needed. Bayer did not immediately respond to a request for comment. Despite the risks amid a rise in diquat's use, the EPA is not reviewing the chemical, and even non-profits that push for tighter pesticide regulations have largely focused their attention elsewhere. Donley said that was in part because US pesticide regulations are so weak that advocates are tied up with battles over ingredients like glyphosate, paraquat and chlorpyrifos – substances that are banned elsewhere but still widely used here. Diquat is 'overshadowed' by those ingredients. 'Other countries have banned diquat, but in the US we're still fighting the fights that Europe won 20 years ago,' Donley said. 'It hasn't gotten to the radar of most groups and that really says a lot about the sad and sorry state of pesticides in the US.' Some advocates have accused the EPA of being captured by industry, and Donley said US pesticide laws were so weak that it was difficult for the agency to ban ingredients, even if the will exists. For example, the agency banned chlorpyrifos in 2022, but a court overturned the decision after industry sued. Moreover, the EPA's pesticides office seems to have a philosophy that states that toxic pesticides are a 'necessary evil', Donley said. 'When you approach an issue from that lens there's only so much you will do,' he said.
